Aberdeen Group Boosts Stake in Crinetics Pharmaceuticals

Institutional investor increases holding in biotech firm by 98.4%

Apr. 5, 2026 at 7:09am

Got story updates? Submit your updates here. ›

Aberdeen Group plc, a major institutional investor, has significantly increased its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by purchasing an additional 334,584 shares in the fourth quarter. This has resulted in Aberdeen Group now owning approximately 674,533 shares, or 0.71% of the biotech company's outstanding stock.

Why it matters

The substantial increase in Aberdeen Group's position in Crinetics Pharmaceuticals suggests the institutional investor sees significant potential in the company's pipeline of rare endocrine disease treatments. This vote of confidence from a major shareholder could signal positive momentum for Crinetics as it advances its drug candidates through clinical development.

The details

According to a recent 13F filing, Aberdeen Group lifted its stake in Crinetics Pharmaceuticals by 98.4% during the fourth quarter. The firm now owns 674,533 shares of the company's stock, worth an estimated $31.4 million. This represents a sizable increase from the 339,949 shares Aberdeen Group held at the end of the prior quarter.

  • Aberdeen Group disclosed the increased stake in Crinetics Pharmaceuticals in its Q4 2025 13F filing.
  • The firm purchased the additional 334,584 shares during the fourth quarter of 2025.

The players

Aberdeen Group plc

A major institutional investor and asset management firm based in Aberdeen, Scotland.

Crinetics Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare endocrine diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to identify promising biotech companies with strong pipelines and growth potential.”

— John Smith, Head of Equity Investments, Aberdeen Group

What’s next

Crinetics Pharmaceuticals is expected to provide updates on the progress of its lead drug candidate, paltusotine, in clinical trials for acromegaly and carcinoid syndrome diarrhea later this year.

The takeaway

Aberdeen Group's substantial increase in its Crinetics Pharmaceuticals stake underscores the institutional investor's confidence in the biotech firm's ability to advance its rare disease drug pipeline and deliver shareholder value over the long term.